NCT05262803View on ClinicalTrials.gov

Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction

PHASE4RecruitingINTERVENTIONAL
Enrollment

2,808

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Myocardial Infarction
Interventions
GENETIC

CYP2C19*2/*3

"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"

OTHER

Shorter DAPT duration

Duration of DAPT is shortened to 3 months

Trial Locations (6)

2100

RECRUITING

The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen

2900

RECRUITING

Herlev and Gentofte University Hospital - Gentofte, Hellerup

4000

RECRUITING

Zealand University Hospital, Roskilde

5000

RECRUITING

Odense University Hospital, Odense

8200

RECRUITING

Aarhus University Hospital, Skejby

9000

RECRUITING

Aalborg University Hospital, Aalborg

All Listed Sponsors
lead

Rikke Sorensen

OTHER